Antibodies, Monoclonal, Humanized (adverse effects) And NotGianluigi Ardissino

List of bibliographic references

Number of relevant bibliographic references: 2.

Ident.	Authors (with country if any)	Title
000643	Josef S. Smolen [Autriche] ; Gerd-Rüdiger Burmester [Allemagne] ; Bernard Combe [France] ; Jeffrey R. Curtis [États-Unis] ; Stephen Hall [Australie] ; Boulos Haraoui [Canada] ; Ronald Van Vollenhoven [Pays-Bas] ; Christopher Cioffi [États-Unis] ; Cécile Ecoffet [Belgique] ; Leon Gervitz [Belgique] ; Lucian Ionescu [Belgique] ; Luke Peterson [États-Unis] ; Roy Fleischmann [États-Unis]	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
000C87	Martin R. Stockler [Australie] ; Felix Hilpert [Allemagne] ; Michael Friedlander [Australie] ; Madeleine T. King [Australie] ; Lari Wenzel [Canada] ; CHEE KHOON LEE [Australie] ; Florence Joly [France] ; Nikolaus De Gregorio [Allemagne] ; José Angel Arranz [Espagne] ; Mansoor Raza Mirza [Danemark] ; Roberto Sorio [Italie] ; Ulrich Freudensprung [Suisse] ; Vesna Sneller [Australie] ; Gill Hales [Australie] ; Eric Pujade-Lauraine [France]	Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024